Compare WSO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | GMAB |
|---|---|---|
| Founded | 1945 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 17.4B |
| IPO Year | N/A | N/A |
| Metric | WSO | GMAB |
|---|---|---|
| Price | $348.13 | $31.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $435.00 | $40.40 |
| AVG Volume (30 Days) | 381.1K | ★ 1.4M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 132.41 |
| EPS | 12.87 | ★ 25.10 |
| Revenue | ★ $7,414,495,000.00 | $3,845,670,022.00 |
| Revenue This Year | N/A | $24.85 |
| Revenue Next Year | $4.21 | $16.67 |
| P/E Ratio | $27.01 | ★ $12.31 |
| Revenue Growth | N/A | ★ 29.57 |
| 52 Week Low | $323.05 | $17.24 |
| 52 Week High | $535.40 | $33.65 |
| Indicator | WSO | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 59.84 |
| Support Level | $337.73 | $31.32 |
| Resistance Level | $356.99 | $32.41 |
| Average True Range (ATR) | 10.38 | 0.64 |
| MACD | 2.70 | 0.11 |
| Stochastic Oscillator | 73.88 | 73.67 |
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.